Overview

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib